Navigation Links
Oral drug sets a new survival standard for bone marrow cancer
Date:11/21/2007

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. The findings demonstrate that with Revlimid, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed. Rush University Medical Center took part in the U.S. study. Results of the study were published November 21 in the New England Journal of Medicine.

In the study, a total of 353 patients were enrolled at 44 centers. Of those patients, 177 were assigned to receive Revlimid (lenalidomide) plus dexamethasone, a steroid hormone, and 176 received a placebo plus dexamethasone. According to the study results, patients who received Revlimid had a median survival of 29.6 months, compared to 20.2 months for the placebo group. In the Revlimid group, 61 percent of patients responded to therapy as compared with 19.9 percent in the placebo group.

According to the International Myeloma Foundation, follow-up data from the U.S. study and a European study report even better results. Patients treated with Revlimid had a median survival of nearly three years (35 months), the longest median survival in this difficult to treat patient group.

"Myeloma, also called multiple myeloma, is of growing interest and concern," said Dr. Stephanie Gregory, the director of the section of Hematology at Rush University Medical Center. "Statistics show the number of diagnoses is increasing in the United States where most cancers are decreasing, and myeloma is being found in increasingly younger patients. These trends give us some urgency in having potent treatments to fight this disease."

Revlimid is an immunomodulatory agent, a drug that can modify or regulate the functioning of the immune system. It is the newest of what are called the novel therapies that have changed the outlook for myeloma patients. It is an oral drug that can be taken at home, and because it targets the cancer cells directly along with factors that support their growth, it does not have the difficult side effects associated with most chemotherapy.

"We are pleased that aggressive efforts to find effective treatments in what was considered a rare, little-known cancer, have led to drugs with broad implications for understanding, treating and eventually curing so many forms of the disease," said Susie Novis, president and co-founder of the International Myeloma Foundation. "Myeloma has been a difficult disease to cure, but with novel therapies we are developing effective, long-term treatments by using multiple drugs in sequence and in various combinations. The addition of a drug with the potency of Revlimid to this equation is especially important."

In Europe and the U.S. Revlimid has been approved for use in multiple myeloma, and in the U.S. it is also approved for a pre-leukemia condition called MDS. It is also being tested in other leukemias and lymphomas and even solid tumors.

Myeloma is a bone marrow cancer that attacks and destroys bone. It accounts for about 16,000 new cases of cancer each year. An estimated 56 thousand people in the United States are living with Myeloma and this year approximately 11,300 deaths from Myeloma are anticipated. While there is no known cure for myeloma, doctors have many approaches to help myeloma patients live better and longer.


'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Mediterranean Diet May Boost Alzheimers Survival
6. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
7. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
8. Communication in cancer world is key to survival
9. Molecular profiling can accurately predict survival in colon cancer patients
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
Breaking Medicine Technology: